NF-κB and STAT3 in glioblastoma: therapeutic targets coming of age

• Published in: Expert review of neurotherapeutics Vol. 14; no. 11; p. 1293
• Main Authors: Gray, G Kenneth, McFarland, Braden C, Nozell, Susan E, Benveniste, Etty N
• Format: Journal Article
• Language: English
• Published: England 01.11.2014
• Subjects: Antineoplastic Agents - therapeutic use; Brain Neoplasms - drug therapy; Brain Neoplasms - metabolism; Glioblastoma - drug therapy; Glioblastoma - metabolism; Humans; NF-kappa B - metabolism; Signal Transduction - physiology; STAT3 Transcription Factor - metabolism; NF-κB; glioblastoma; signaling; neurotherapeutics; STAT3
• ISSN: 1744-8360
• DOI: 10.1586/14737175.2014.964211

Since we last addressed the roles of NF-κB and JAK/STAT3 signaling in glioblastoma (GBM) 5 years ago, tremendous strides have been made in the understanding of these two pathways in glioma biology. Contributing to prosurvival mechanisms, cancer stem cell maintenance and treatment resistance, both NF-κB and STAT3 have been characterized as major drivers of GBM. In this review, we address general improvements in the molecular understanding of GBM, the structure of NF-κB and STAT3 signaling, the ways in which these pathways contribute to GBM and advances in preclinical and clinical targeting of these two signaling cascades.